Ignite Creation Date:
2024-05-06 @ 4:22 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04965493
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2021-07-15
Brief Title:
A Trial of Pirtobrutinib LOXO-305 Plus Venetoclax and Rituximab PVR Versus Venetoclax and Rituximab VR in Previously Treated Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma CLLSLL
Sponsor:
Loxo Oncology Inc
Organization:
Eli Lilly and Company
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-09-20
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-07-15
First Submit QC Date:
July 15 2021
Study First Post Date:
2021-07-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-01
Last Update Post Date:
2024-07-03
Last Update Post Date Type:
ACTUAL